

Rui-Lan Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/697677/publications.pdf>

Version: 2024-02-01

56
papers

1,951
citations

257450

24
h-index

254184

43
g-index

57
all docs

57
docs citations

57
times ranked

3406
citing authors

#	ARTICLE	IF	CITATIONS
1	Epigenetic biomarker and drug development in gynecological cancers. , 2022, , 223-255.		0
2	Genome-wide analysis of cervical secretions obtained during embryo transfer reveals the association between deoxyribonucleic acid methylation and pregnancy outcomes. F&S Science, 2022, 3, 74-83.	0.9	3
3	Epigenomic Profiling of Epithelial Ovarian Cancer Stem-Cell Differentiation Reveals GPD1 Associated Immune Suppressive Microenvironment and Poor Prognosis. International Journal of Molecular Sciences, 2022, 23, 5120.	4.1	3
4	Epigenomic Analysis Reveals the KCNK9 Potassium Channel as a Potential Therapeutic Target for Adenomyosis. International Journal of Molecular Sciences, 2022, 23, 5973.	4.1	3
5	BHLHE22 Expression Is Associated with a Proinflammatory Immune Microenvironment and Confers a Favorable Prognosis in Endometrial Cancer. International Journal of Molecular Sciences, 2022, 23, 7158.	4.1	2
6	NKX6-1 mediates cancer stem-like properties and regulates sonic hedgehog signaling in leiomyosarcoma. Journal of Biomedical Science, 2021, 28, 32.	7.0	6
7	Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report. Journal of Ovarian Research, 2020, 13, 143.	3.0	9
8	The role of GRHL2 and epigenetic remodeling in epithelialâ€mesenchymal plasticity in ovarian cancer cells. Communications Biology, 2019, 2, 272.	4.4	58
9	Transition from multiport to single-site surgery: A single institution experience in robotic supracervical hysterectomy for benign gynecological diseases. Taiwanese Journal of Obstetrics and Gynecology, 2019, 58, 514-519.	1.3	7
10	Paired Box-1 (PAX1) Activates Multiple Phosphatases and Inhibits Kinase Cascades in Cervical Cancer. Scientific Reports, 2019, 9, 9195.	3.3	24
11	E2F6 functions as a competing endogenous RNA, and transcriptional repressor, to promote ovarian cancer stemness. Cancer Science, 2019, 110, 1085-1095.	3.9	27
12	TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2Î± as a therapeutic target. Journal of Pathology, 2019, 248, 363-376.	4.5	23
13	TET1 promotes 5hmC-dependent stemness, and inhibits a 5hmC-independent epithelial-mesenchymal transition, in cervical precancerous lesions. Cancer Letters, 2019, 450, 53-62.	7.2	33
14	Combined genetic mutations and DNA-methylated genes as biomarkers for endometrial cancer detection from cervical scrapings. Clinical Epigenetics, 2019, 11, 170.	4.1	28
15	Ovarian cancer detection by DNA methylation in cervical scrapings. Clinical Epigenetics, 2019, 11, 166.	4.1	22
16	Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors. International Journal of Cancer, 2018, 143, 355-367.	5.1	12
17	GATA3 as a master regulator and therapeutic target in ovarian highâ€grade serous carcinoma stem cells. International Journal of Cancer, 2018, 143, 3106-3119.	5.1	31
18	Epigenetic loss of heparan sulfate 3â€sulfation sensitizes ovarian carcinoma to oncogenic signals and predicts prognosis. International Journal of Cancer, 2018, 143, 1943-1953.	5.1	11

#	ARTICLE	IF	CITATIONS
19	Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface. <i>Nature Communications</i> , 2018, 9, 2270.	12.8	159
20	Idiopathic Low Ovarian Reserve Is Associated with More Frequent Positive Thyroid Peroxidase Antibodies. <i>Thyroid</i> , 2017, 27, 1194-1200.	4.5	46
21	Loss of discoidin domain receptor 1 (DDR1) via CpG methylation during EMT in epithelial ovarian cancer. <i>Gene</i> , 2017, 635, 9-15.	2.2	20
22	Integrated Epigenomics Analysis Reveals a DNA Methylation Panel for Endometrial Cancer Detection Using Cervical Scrapings. <i>Clinical Cancer Research</i> , 2017, 23, 263-272.	7.0	64
23	Genotype-specific methylation of HPV in cervical intraepithelial neoplasia. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e56.	2.2	19
24	Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer. <i>PLoS ONE</i> , 2017, 12, e0182166.	2.5	39
25	Methylomics of nitroxidative stress on precancerous cells reveals DNA methylation alteration at the transition from in situ to invasive cervical cancer. <i>Oncotarget</i> , 2017, 8, 65281-65291.	1.8	9
26	An epigenetic signature of adhesion molecules predicts poor prognosis of ovarian cancer patients. <i>Oncotarget</i> , 2017, 8, 53432-53449.	1.8	25
27	Platelet-Derived Growth Factor in the Ovarian Follicle Attracts the Stromal Cells of the Fallopian Tube Fimbriae. <i>PLoS ONE</i> , 2016, 11, e0158266.	2.5	7
28	Paired boxed gene 1 expression: A single potential biomarker for differentiating endometrial lesions associated with favorable outcomes in patients with endometrial carcinoma. <i>Journal of Obstetrics and Gynaecology Research</i> , 2016, 42, 1159-1167.	1.3	3
29	The cytokine-cosmc signaling axis upregulates the tumor-associated carbohydrate antigen Tn. <i>Oncotarget</i> , 2016, 7, 61930-61944.	1.8	4
30	Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 8993-9006.	1.8	66
31	Global methylation silencing of clustered <i>protoadherin</i> genes in cervical cancer: serving as diagnostic markers comparable to HPV. <i>Cancer Medicine</i> , 2015, 4, 43-55.	2.8	40
32	Hypermethylation of the TGF- β target, ABCA1 is associated with poor prognosis in ovarian cancer patients. <i>Clinical Epigenetics</i> , 2015, 7, 1.	4.1	133
33	Genome-wide DNA methylation analysis reveals estrogen-mediated epigenetic repression of metallothionein-1 gene cluster in breast cancer. <i>Clinical Epigenetics</i> , 2015, 7, 13.	4.1	38
34	Concordance analysis of methylation biomarkers detection in self-collected and physician-collected samples in cervical neoplasm. <i>BMC Cancer</i> , 2015, 15, 418.	2.6	24
35	Triage of high-risk human papillomavirus-positive women by methylated POU4F3. <i>Clinical Epigenetics</i> , 2015, 7, 85.	4.1	26
36	MeDIP-on-Chip for Methylation Profiling. <i>Methods in Molecular Biology</i> , 2015, 1249, 281-290.	0.9	7

#	ARTICLE	IF	CITATIONS
37	Abstract 1128: TET1-mediated epigenetic reprogramming switches metabolism and promotes malignant phenotypes of ovarian cancer. , 2015, , .		0
38	Downregulation of <i>miR-29</i> contributes to cisplatin resistance of ovarian cancer cells. International Journal of Cancer, 2014, 134, 542-551.	5.1	116
39	DNA methylation as a biomarker for the detection of hidden carcinoma in endometrial atypical hyperplasia. Gynecologic Oncology, 2014, 135, 552-559.	1.4	28
40	ATL. International Journal of Gynecological Cancer, 2014, 24, 201-209.	2.5	63
41	Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cancer. Taiwanese Journal of Obstetrics and Gynecology, 2014, 53, 30-34.	1.3	13
42	Hypomethylation signature of tumor-initiating cells predicts poor prognosis of ovarian cancer patients. Human Molecular Genetics, 2014, 23, 1894-1906.	2.9	56
43	Methylomics analysis identifies epigenetically silenced genes and implies an activation of β -catenin signaling in cervical cancer. International Journal of Cancer, 2014, 135, 117-127.	5.1	59
44	Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers. Epigenetics, 2013, 8, 624-634.	2.7	51
45	Promoter Hypomethylation of EpCAM-Regulated <i>Bone Morphogenetic Protein</i> Gene Family in Recurrent Endometrial Cancer. Clinical Cancer Research, 2013, 19, 6272-6285.	7.0	37
46	Ovarian cancer stem-like cells with induced translineage-differentiation capacity and are suppressed by alkaline phosphatase inhibitor. Oncotarget, 2013, 4, 2366-2382.	1.8	20
47	Methylomic Analysis Identifies Frequent DNA Methylation of Zinc Finger Protein 582 (ZNF582) in Cervical Neoplasms. PLoS ONE, 2012, 7, e41060.	2.5	72
48	Growth Inhibition of Ovarian Tumor-Initiating Cells by Niclosamide. Molecular Cancer Therapeutics, 2012, 11, 1703-1712.	4.1	106
49	Abstract 1110: Effect of miR-29 on cisplatin sensitivity of ovarian cancer cells. , 2012, , .		0
50	Presacral teratoma in a Curarrino syndrome woman with an unreported insertion in MNX1 gene. Taiwanese Journal of Obstetrics and Gynecology, 2011, 50, 512-514.	1.3	8
51	Squamous cell carcinoma arising from an ovarian teratoma related to human papillomavirus infection: Using a PCR-based reverse-blot assay. Taiwanese Journal of Obstetrics and Gynecology, 2011, 50, 543-545.	1.3	7
52	Abstract 3433: Disruption of TGF- β signaling induces demethylation of E-cadherin promoter and reverses mesenchymal phenotype in ovarian cancer. Cancer Research, 2011, 71, 3433-3433.	0.9	1
53	Quantitative DNA methylation analysis detects cervical intraepithelial neoplasms type 3 and worse. Cancer, 2010, 116, 4266-4274.	4.1	76
54	Identification of novel DNA methylation markers in cervical cancer. International Journal of Cancer, 2008, 123, 161-167.	5.1	188

#	ARTICLE	IF	CITATIONS
55	Novel germline and somatic mutations of the MSH2 gene in hereditary non-polyposis colorectal cancer. Clinical Genetics, 2007, 71, 190-192.	2.0	2
56	Multiple epithelial and nonepithelial tumors in hereditary nonpolyposis colorectal cancer: characterization of germline and somatic mutations of the MSH2 gene and heterogeneity of replication error phenotypes. Cancer Genetics and Cytogenetics, 2004, 153, 108-114.	1.0	17